John Bhatt

John Bhatt has investigated PARP inhibitors as a therapeutic strategy for BRCA1/2-mutated HR+ breast cancers, examining their activity as single agents and in combination with endocrine therapy and CDK4/6 inhibitors. His research has explored the intersection of BRCA mutation carrier status, hormone receptor expression, and responses to PARP inhibition in the metastatic setting, characterized through both clinical trials and translational biomarker studies. He has studied the clinical activity of olaparib and niraparib in patients with germline BRCA-mutated HR+/HER2- metastatic breast cancer, and the combination of PARP inhibitors with CDK4/6 inhibitors to leverage synthetic lethality in the context of CDK-induced replication stress. His work contributes to precision treatment strategies for BRCA-mutated HR+ breast cancer beyond traditional endocrine-based approaches.